Page 2 - Metropolis Healthcare

Chose growth over profitability: Core Diagnostics' Zoya on acquisition

India has several venture-backed startups for whom the natural consequence is to have an exit, and between profitability and growth in the journey ahead, "we opted for the latter", Zoya Brar, founder of Core Diagnostics, which was recently acquired by Metropolis Healthcare, said. Metropolis Healthcare, one of India's leading diagnostics chains, acquired specialised diagnostics company Core Diagnostics for Rs 246.8 crore last month. "For an organisation to scale, it can either do it organically or inorganically. Since we have a number of venture-backed startups (in India), the natural consequence is, there needs to be an exit. And while IPOs are an option, they need a certain volume and scale before it makes sense. So we will continue to see consolidation," Brar told PTI. "Most importantly, incumbents like Metropolis need to constantly differentiate themselves to remain ahead of the competitive landscape and one simple way to do that is to acquire insurgents that have built an ...

F&O Market: Union Bank, Dabur see short build-up as Nifty tumbles 300pts

Union Bank stock futures plunged nearly 8% on the back of 54% increase in OI. On the other hand, Dr. Lal Path Labs and Metropolis Health witnessed long build-up on Monday; shows derivatives data.

Core acquisition adds to Metropolis Healthcare's long-term growth plans

Market share gains in the B2C portfolio are visible and Tier III+ markets are likely to contribute to the patient volume growth guidance

Axis Bank, Nippon AMC, Maruti: JM Financial picks 12 stocks to buy for 2025

From the robust banking and financial services domain, Axis Bank and Nippon AMC make the cut. The auto industry sees Maruti Suzuki and Samvardhana Motherson International (SAMIL) in the spotlight

Metropolis Healthcare shares rise 3% after acquiring Core Diagnostics

Shares of diagnostic firm Metropolis Healthcare surged 2.88 per cent at Rs 2,250 per share on the BSE in Tuesday's intraday trade

Stocks to Watch on Dec 10: Vi, Metropolis, MapmyIndia, TaMo, LIC, PFC

Stocks to Watch on Dec 10: From Vodafone Idea (Vi) to Tata Motors, here is a list of stocks that will remain in limelight today

Metropolis Healthcare adds Core strength to specialty cancer diagnostics

Buys 100% stake in Core Diagnostics through cash, stock for Rs 247 crore

Metropolis Healthcare to acquire Core Diagnostics for Rs 247 crore

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

Metropolis Healthcare plans to expand reach to 1,000 towns in 18 months

The firm aims to strengthen its presence in tier 2 and tier 3 cities, supported by an investment of approximately Rs 65 crore

Indian population saw 30% increase in ANAs post Covid-19, says study

ANAs are proteins produced by the immune system that mistakenly target the body's own cells, leading to tissue damage and autoimmune diseases like rheumatoid arthritis and thyroid disorders

Not looking to bring any strategic investor on board now: Ameera Shah

In a video interview with Sohini Das, Shah outlines her plans for international business, and also why she got in a new CEO

Patient influx, test volumes raise Metropolis Healthcare's profit by 31%

Commenting on the results, Ameera Shah, Executive Chairperson and Whole-time Director, Metropolis Healthcare, said that the company has consistently achieved high growth in patient volume

5 stocks with long buildup: AU SFB, Marico, TVS Motor may surge up to 22%

Aditya Birla Fashion, AU Small Finance Bank, Metropolis, Marico and TVS Motor have seen steady rise in stock price, backed by rise in open interest, thus indicating long buildup at these counters in t

Metropolis Health up 8% post Q4 nos; Ameera appointed Executive Chairperson

Metropolis Health stock update: Metropolis Healthcare stock price hit a fresh record high of Rs 2,049 on Wednesday. Ameera Shah takes charge as executive chairperson and whole-time director

RIL, Sun Pharma, HDFC Bank, BHEL among 11 stocks to monitor on May 22

At 7:09 AM, GIFT Nifty futures indicated a modest uptick of 25 points, trading at 22,626 against Nifty futures

Metropolis Healthcare revenue up 17%, targets industry-leading growth

In Q4, the business-to-consumers (B2C) revenues grew by approximately 20 per cent Y-o-Y, and revenues from the Mumbai market also saw 20 per cent growth

Metropolis Healthcare gets Rs 24 cr income tax demand from Mumbai officials

Metropolis Healthcare Ltd on Monday said it has received a Rs 24.46 crore income tax demand from the income tax authority. An income tax demand of Rs 24.46 crore (tax plus interest) has been raised by the Assistant Commissioner of Income Tax, Mumbai, Income Tax Department (ACIT) for assessment year (AY) 2023-24, Metropolis Healthcare said in a regulatory filing. The actual demand for AY 2023-24 will come to Rs 24.19 crore after adjusting rectification of Rs 27 lakh pertaining to AY 2023-24, it added. For the Rs 27 lakh demand, tax plus interest, for AY 2023-24, the company has brought to the notice of ACIT that an error has occurred during the computation of tax and ACIT has not granted credit for certain taxes already paid by the company. Metropolis Healthcare further said it has filed an application for rectification and issuance of the rectification order on account of TDS credit, advance tax, and self-assessment tax credits not allowed. ACIT has accepted the application and is

Metropolis Healthcare Q3 results: PAT down 24% due to Chennai floods

On a sequential basis, the company exhibited a 5.63 per cent decline in revenue along with PAT, which declined by 23.41 per cent

Metropolis Healthcare PAT declines 12%, consolidated revenue up 2.7%

EBITDA stood at Rs 77.8 crore, declining 6.2 per cent year-on-year and growing 16.1 per cent sequentially

Metropolis Healthcare eyes 60% revenue from B2C business in next 2-3 years

The diagnostic player has also taken price hikes in the range of 4-5 percent in the last three years